Please assess the completion status of the following clinical trial:

Trial Title: A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Female aged ≥18 and ≤45 years with a viable pregnancy.~2. Provide signed informed consent as described in the protocol and willing to comply with all study visits and requirements.~3. Diagnosis of ICP.~4. (Part 2 only) Qualified level of pruritus associated with ICP, during screening.~Exclusion Criteria:~1. At the time of either the screening or baseline visit, decision has already been made to deliver within the next 7 days, for any indication.~2. Known non-reassuring fetal status based upon antepartum testing (e.g., NST/CTG or BPP) at or within 7 days before the baseline visit.~3. Known fetal anomaly likely to result in intrauterine fetal demise or neonatal death within the first 30 days of life.~4. Participating in another ongoing interventional clinical study at screening or planning to participate in another contemporaneous interventional clinical study while participating in this study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Part 1 Arm 1 - Volixibat 20mg (Type: EXPERIMENTAL): Participants randomized to this arm will receive volixibat 20mg twice daily.
- Part 1 Arm 2 - Volixibat 80mg (Type: EXPERIMENTAL): Participants randomized to this arm will receive volixibat 80mg twice daily.
- Part 2 Arm 1 - Volixibat Selected Dose mg (Type: EXPERIMENTAL): Participants randomized to this arm will receive volixibat selected dose (mg) twice daily.
- Part 2 Arm 2 - Placebo (Placebo Comparator) (Type: PLACEBO_COMPARATOR): Participants in this arm will receive capsules matched to the study drug minus the active volixibat substance, twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).